Temasek to launch 10-year US dollar bond offering

Only qualified institutional investors and buyers inside and outside the US can buy the bonds.

Temasek Holdings intends to offer a 10-year benchmark T2028-USD Temasek Bond today through its wholly-owned subsidiary, Temasek Financial (I) Limited (TFin-I). It will be offered to qualified institutional investors and buyers inside and outside the US under the US Securities Act of 1993.

According to an announcement, the bond under its US$20b Guaranteed Global Medium Term Note Program will be unconditionally and irrevocably guaranteed by Temasek.

TFin-I intends to provide the net proceeds from the issuance of the T2028-USD Temasek Bond to Temasek and its investment holding companies to fund their ordinary course of business.

The application will be made for the listing and quotation of the T2028-USD Temasek Bond on the Official List of the Singapore Exchange Securities Trading Limited (the SGX-ST).  

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare